Bladder Cancer Coverage from Every Angle

Shilpa Gupta, MD, on a 4-Year Update From EV-103: Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma

Posted: Sunday, June 4, 2023

Shilpa Gupta, MD, of Cleveland Clinic, discusses the 4-year follow-up data from EV-103 on the use of the antibody-drug conjugate enfortumab vedotin-ejfv plus the PD-1 inhibitor pembrolizumab in the first-line treatment of cisplatin-ineligible, locally advanced or metastatic urothelial carcinoma. The updated trial findings showed the continued benefits of this combination immunotherapy in this patient population.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.